Home
|
Learning Center
|
中文版
Publications
站内成果搜索:
搜索
FOLFIRINOX for Locally Advanced Pancreatic Adenocarcinoma: Results of an AGEO Multicenter Prospective Observational Cohort
FOLFOX Enables High Resectability and Excellent Prognosis for Initially Unresectable Colorectal Liver Metastases
FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial
FOLFOX6方案治疗晚期结直肠癌的疗效与安全性分析
FOLFOX4方案联合益气健脾汤治疗结直肠癌的临床研究
FOLFIRI方案治疗胃癌异时性卵巢转移的疗效
FOLFIRINOX方案治疗晚期胰腺癌不良反应的观察与护理
FOLFOX4方案和DF方案治疗晚期胃癌的比较
FOLFOX4方案治疗老年晚期大肠癌疗效分析及不良反应观察
FOLFOX4方案化疗对结直肠癌患者免疫细胞数的影响
FOLFIRI方案化疗对肾上腺皮质激素的动态影响
FOLFOX_4方案治疗晚期胃癌的临床疗效
FOLFIRI Plus Bevacizumab 5 mg/kg Versus 10 mg/kg as Second-line Therapy in Patients with Metastatic Colorectal Cancer Who Have Failed First-line Bevacizumab Plus Oxaliplatin-based Therapy: A Randomized Phase III Study (EAGLE Study)
FOLFIRINOX: A Great Leap Forward, but for Whom?
FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience
FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3
FOLFIRINOX-Based Neoadjuvant Therapy in Borderline Resectable or Unresectable Pancreatic Cancer A Meta-Analytical Review of Published Studies
FOLFIRINOX in Locally Advanced Pancreatic Cancer: The Massachusetts General Hospital Cancer Center Experience
FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study
FOLFIRI and sunitinib as first-line treatment in metastatic colorectal cancer patients with liver metastases - a CESAR phase II study including pharmacokinetic, biomarker, and imaging data
FOLFIRI Chemotherapy in Patients with Advanced Non Resectable Esophageal or Junctional Adenocarcinoma: A Pilot Study
FOLFOX as Adjuvant Chemotherapy after Curative Resection of Distant Metastases in Patients with Colorectal Cancer
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts
FOLFOX4 in the Adjuvant Treatment of Colon Cancer in Asian Patients
FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort
FOLFOX-4 Regimen or Single-agent Gemcitabine as First-line Chemotherapy in Advanced Biliary Tract Cancer
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306
FOLFOX-4 Chemotherapy for Patients With Unresectable or Relapsed Peritoneal Pseudomyxoma
FOLFIRINOX for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: The Royal Marsden Experience
FOLFIRINOX: Desert, Oasis, or Mirage?
FOLFIRI-Bevacizumab As First-Line Chemotherapy in 3500 Patients With Advanced Colorectal Cancer: A Pooled Analysis of 29 Published Trials
FOLFIRI with cetuximab or bevacizumab: FIRE-3 Reply
FOLFOX regimen plus dendritic cells-cytokine-induced killer cells immunotherapy for the treatment of colorectal cancer: a meta-analysis
FOLFOXIRI plus bevacizumab as conversion-therapy for liver metastases in colorectal cancer: A necessity?
FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer REPLY
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study
FOLFOX6方案治疗结肠癌术后的护理效果
FOLFOX6方案与XELOX辅助化疗方案在胃癌术后的应用及生存差异
FOLFOX plus Nab-Paclitaxel (FOLFOX-A) for Advanced Pancreatic Cancer A Brown University Oncology Research Group Phase I Study
FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer
FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer
FOLFIRINOX: A Great Leap Forward, but for Whom? Reply
FOLFIRINOX in Locally Advanced Pancreatic Cancer The Starting Point for Questioning
FOLFIRINOX: A Small Step or a Great Leap Forward?
FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS wild-type metastatic colorectal cancer: A retrospective subgroup analysis of the CRYSTAL study
FOLFOX4 in the treatment of metastatic colorectal cancer in elderly patients: A prospective study
FOLFOX and intensified split-course chemoradiation as initial treatment for rectal cancer with synchronous metastases
FOLFIRINOX in Locally Advanced and Metastatic Pancreatic Cancer: A Single Centre Cohort Study